Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 145

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 145
---
 meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. ParentCo’s directors are divided among the three classes as follows:

| ● | the Class I director is Mr. Nicholas Fernandez and Dr. Ji Yeon Baek, with a term that will expire at the annual meeting of stockholders to be held in 2026; |

| ● | the Class II director is Dr. Eun Sook Lee, with a term that will expire at the annual meeting of stockholders to be held in 2027; and |

| ● | the Class III director is Mr. Chris Kim, with a term that will expire at the annual meeting of stockholders to be held in 2028. |

Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of the ParentCo Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. Director Independence ParentCo is required to comply with the applicable rules of Nasdaq in determining whether a director is independent. ParentCo undertook a review of the independence of the individuals named above and has determined that each of Dr. Eun Sook Lee, Dr. Ji Yeon Baek and Nicholas Fernandez qualifies as “independent” as defined under the applicable Nasdaq rules. Role of the Board in Risk Oversight One of the key functions of the ParentCo Board is informed oversight of ParentCo’s risk management process. The ParentCo Board does not anticipate having a standing risk management committee, but rather anticipates administering this oversight function directly through the ParentCo Board as a whole, as well as through various standing committees of the ParentCo Board that address risks inherent in their respective areas of oversight. In particular, the ParentCo Board is responsible for monitoring and assessing strategic risk exposure and ParentCo’s audit committee will have the responsibility to consider and discuss ParentCo’s major financial risk exposures and the steps its management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements.

93

ParentCo’s compensation committee also assesses and monitors whether ParentCo’s compensation plans, policies and programs comply with applicable legal and regulatory requirements. Committees of the ParentCo Board The ParentCo Board